Sep. 4 at 5:38 PM
$BSX Stepping aside here and reassessing near-term risk and operational reality...
When Boston Scientific first filed their 8-K disclosing a cybersecurity incident that disrupted order processing, my initial take was to treat it as standard headline noise... simple order deferrals rather than a structural issue. But as I've dug deeper into the supply-chain data and operational precedents across the sector, intellectual honesty requires admitting this disruption could easily carry more weight than first meets the eye. Ultimately, when earnings roll around, the numbers on the page and how the tape reacts to them are all that matter.
I have been vocal about my long-term bullish thesis on BSX sharing my entries, options structures, and sizing as we accumulated shares off the washed-out lows. We caught a solid rebound off the bottom. But active risk management requires the discipline to step back when the fundamental picture introduces operational unknowns that can't be reliably quantified:
• The sector precedent: Unfortunately, this isn't an isolated event; we've seen a clear wave of attacks hitting peers across the medtech space this year, including
$SYK $ABT $ISRG and
$MDT . Stryker’s experience in March is a prime benchmark: their breach crippled ordering, manufacturing, and shipping for weeks, resulting in a Q1 top-and-bottom-line miss. On their earnings call, Stryker CEO Kevin Lobo stated directly:
"The cyber incident had a big impact on our results and affected each of our businesses differently given their varied go-to-market models and processes to record revenue. This resulted in distortions in our first-quarter results that will normalize over the course of the year."
• Regulatory & operational friction: In medtech, operational recovery isn't just about restoring an IT network or turning servers back on. Manufacturing lines operate inside strict, FDA-validated quality environments. Recalibrating processes, validating batch releases, and clearing backlogs takes time. With key facilities like Cork, Ireland sending production workers home during the outage, the flow of goods has faced measurable friction that will likely spill into quarterly numbers.
• Context on insider buying: Insiders have shown substantial conviction on the way down... CEO Mike Mahoney deployed roughly
$9.0 million of personal capital on the open market in early August, alongside multiple director purchases. However, those transactions occurred before this cyber disruption hit. Leadership bought based on long-term valuation and turnaround pipeline visibility, not with foresight of a sudden operational shutdown.
All told, I remain a believer in the Boston Scientific franchise long-term, but turning a blind eye to supply-chain drag and near-term margin risk is a fast way to give back hard-earned profits. I have harvested gains off the washout lows, unwound near-term exposure, and stepped aside for now. If the stock grinds higher without me, so be it... I’d rather let the dust settle and evaluate the actual financial impact in black and white before re-engaging.
Execution discipline over emotion. Good luck out there... and trade 'em well. 😊
